Urinary sCD25 as a biomarker of lupus nephritis disease activity

Lupus

Volumn 24, Issue 3, 2015, Pages 273-279

  Gupta, R ^a   Yadav, A ^a   Misra, R ^a   Aggarwal, A ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

biomarker; CD25; nephritis; SLE; urine

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; DOUBLE STRANDED DNA ANTIBODY; INTERLEUKIN 2 RECEPTOR ALPHA; SOLUBLE CD25 ANTIGEN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; IL2RA PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; URINALYSIS; CASE CONTROL STUDY; CHILD; CLINICAL TRIAL; MIDDLE AGED; PROSPECTIVE STUDY; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; CASE-CONTROL STUDIES; CHILD; FEMALE; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84922638800     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314555174     Document Type: Article

References (14)

1. Martin M, Schwinzer R, Schellekens H, et al. Glomerular mesangial cells in local inflammation. Induction of the expression of MHC class II antigens by IFN-gamma. J Immunol. 1989 ; 142: 1887-1894
2. Chen H-S, Wu M-S, Yen T-S, et al. Soluble interleukin-2 receptor in patients with glomerular diseases. Postgrad Med J. 1995 ; 71: 617-622
3. Tsai C-Y, Wu T-H, Sun K-H, et al. Increased excretion of soluble interleukin 2 receptors and free light chain immunoglobulins in the urine of patients with active lupus nephritis. Ann Rheum Dis. 1992 ; 51: 168-172
4. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277
5. Nasari H, Ahmadi A, Baradaran A, et al. Clinicopathological correlations in lupus nephritis; a single center experience. J Nephropathol. 2014 ; 3: 115-120
6. Chan EY-T, Lau C-S, Zola H. Expression of IL-2R, IL-4R, IL-6R on peripheral blood lymphocytes in systemic lupus erythematosus and correlation with disease activity: A prospective study. J Clin Pathol. 1996 ; 49: 660-663
7. Ter borg EJ, Horst G, Limburg PC, et al. Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus. Clin Exp Immunol. 1990 ; 82: 21-26
8. Tokano Y, Murashima A, Takasaki Y, et al. Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus. Ann Rheum Dis. 1989 ; 48: 803-809
9. Spronk PE, ter Borg EJ, Huitema MG, et al. Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: A prospective study. Ann Rheum Dis. 1994 ; 53: 235-239
10. Wolf RE, Brelsford WG. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum. 1988 ; 31: 729-735
11. El-Shafey EM, El-Nagar GF, El-Bendary AS, et al. Serum soluble interleukin-2 receptor alpha in systemic lupus erythematosus. Iran J Kidney Dis. 2008 ; 2: 80-85
12. Laut J, Senitzer D, Petrucci R, et al. Soluble interleukin-2 receptor levels in lupus nephritis. Clin Nephrol. 1992 ; 38: 179-184
13. Davas EM, Tsirogianni A, Kappou I, et al. Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus. Clin Rheumatol. 1999 ; 18: 17-22
14. Wong KL, Wong RP. Serum soluble interleukin 2 receptor in systemic lupus erythematosus: Effects of disease activity and infection. Ann Rheum Dis. 1991 ; 50: 706-709